
Willxone S 250mg/125mg Injection
Marketer
Alvoncare Pharma
Salt Composition
Ceftriaxone (250mg) + Sulbactam (125mg)
Overview Willxone S 250mg/125mg Injection
Combiflox 250mg/125mg Injection is a dual-action antibiotic used to combat diverse bacterial infections. Its mechanism inhibits microbial growth, thereby curbing infection spread. Administration of Combiflox 250mg/125mg Injection must always be under a healthcare provider's guidance. Strict adherence to the prescribed dosage schedule is crucial; complete the entire course of treatment, regardless of symptom improvement. Premature cessation may compromise efficacy. Potential side effects include, but are not limited to, nausea, vomiting, diarrhea, and dyspepsia. Worsening side effects necessitate immediate medical consultation. Seek immediate medical attention for allergic reactions such as rashes, itching, swelling, or respiratory distress. Inform your physician of all current medications before commencing treatment. Pregnant or lactating individuals require prior medical consultation. Alcohol consumption should be avoided due to potential increased drowsiness. While generally non-impairing to driving ability, refrain from driving if drowsiness or dizziness occurs. Adequate rest, a nutritious diet, and ample hydration are vital for optimal recovery. Your doctor may order laboratory tests to monitor the medication's effects.
Uses of Willxone S 250mg/125mg Injection
Infections caused by bacteria
Major Benefits of Willxone S 250mg/125mg Injection:
Administering this medication will be handled by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Willxone S 250mg/125mg Injection:
- Increased white blood cell count (eosinophils)
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Rash
- Diarrhea
- Increased liver enzymes
- Injection site reactions (pain, swelling, redness)
How to use Willxone S 250mg/125mg Injection:
The medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.
How Willxone S 250mg/125mg Injection works:
Ceftriaxone and Sulbactam, the components of Willxone S 250mg/125mg Injection, act synergistically. Ceftriaxone, a cephalosporin antibiotic, disrupts bacterial cell wall synthesis, hindering bacterial survival. The beta-lactamase inhibitor, Sulbactam, counters bacterial resistance mechanisms, thereby bolstering Ceftriaxone's effectiveness.
SAFETY ADVICE
AlcoholSAFE
Concurrent use of Willxone S 250mg/125mg Injection and alcohol poses no known adverse reactions.
PregnancySAFE IF PRESCRIBED
The injectable medication Willxone S 250mg/125mg is typically deemed safe for use during gestation. Preclinical trials in animals revealed minimal or absent negative impacts on fetal development; nevertheless, data from human trials remain scarce.
Breast feedingCAUTION
Administering Willxone S 250mg/125mg Injection to breastfeeding mothers requires careful consideration. Lactation should be temporarily discontinued throughout the mother's treatment course and until the medication is fully cleared from her system.
DrivingUNSAFE
Administering Willxone S 250mg/125mg Injection can induce drowsiness, blurred vision, and dizziness. Refrain from driving if these effects manifest.
KidneyCONSULT YOUR DOCTOR
Insufficient data exists regarding the administration of Willxone S 250mg/125mg Injection to individuals with renal impairment. Physician consultation is advised.
LiverCAUTION
Patients with severe hepatic impairment should use Willxone S 250mg/125mg Injection cautiously, potentially requiring dosage modification. Physician consultation is advised. Dosage alteration for Willxone S 250mg/125mg Injection is unnecessary in individuals with mild to moderate liver dysfunction.
What if you forget to take Willxone S 250mg/125mg Injection :
Should you forget a scheduled dose of Willxone S 250mg/125mg Injection, seek your physician's advice.
Facts to Know About Willxone S 250mg/125mg Injection
| Label | Value |
|---|---|
| Potential for Dependence | None. |
| Type of Medication | Agents against infection |
